-
Babapoor S, Neef T, Mittelholzer C, Girshick T, Garmendia A, Shang H, Khan M I, Burkhard P, 2012: A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection[J]. Influenza Res Treat, 2011, 126794-. doi: 10.1155/2011/126794.Epub2012Jan12
-
Bessa J, Schmitz N, Hinton H J, Schwarz K, Jegerlehner A, Bachmann M F, 2008: Efficient induction of mucosal and systemicimmune responses by virus-like particles administered intranasally: implications for vaccine design[J]. Eur J Immunol, 38, 114-126. doi: 10.1002/eji.200636959
-
Bijker M S, van den Eeden S J, Franken K L, Melief C J, Offringa R, van der Burg S H, 2007: CD8+ CTL priming by exact peptideepitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity[J]. J Immunol, 179, 5033-5040. doi: 10.4049/jimmunol.179.8.5033
-
Black R A, Rota P A, Gorodkova N, Klenk H D, Kendal A P, 1993: Antibody response to the M2 protein of influenza A virus expressed in insect cells[J]. J Gen Virol, 74, 143-146.
-
Bolhassani A, Rafati S, 2008: Heat-shock proteins as powerful weapons in vaccine development[J]. Expert Rev Vaccines, 7, 1185-1199. doi: 10.1586/14760584.7.8.1185
-
Carrat F, Vergu E, Ferguson N M, Lemaitre M, Cauchemez S, Leach S, Valleron A J, 2008: Time lines of infection and disease in human influenza: a review of volunteer challenge studies[J]. Am J Epidemiol, 167, 775-785. doi: 10.1586/14760584.7.8.1185
-
Chen C H, Wang T L, Hung C F, Yang Y, Young R A, Pardoll D M, Wu T C, 2000: Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene[J]. Cancer Res, 60, 1035-1042.
-
Cox N J, Subbarao K, 2000: Global epidemiology of influenza:past and present[J]. Annu Rev Med, 51, 407-421. doi: 10.1146/annurev.med.51.1.407
-
De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W, 2005: Universal influenza A vaccine: optimizationof M2-based constructs[J]. Virology, 337, 149-161. doi: 10.1016/j.virol.2005.04.004
-
De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, Londono-Arcila P, Fiers W, Saelens X, 2008: Universal influenzaA M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies[J]. Vaccine, 26, 6503-6507. doi: 10.1016/j.vaccine.2008.09.038
-
De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, Vandekerckhove J, Fiers W, Saelens X, 2008: An influenza A vaccine based on tetrameric ectodomain of matrix protein 2[J]. J Biol Chem, 283, 11382-11387. doi: 10.1074/jbc.M800650200
-
Ebrahimi S M, Tebianian M, 2010: Heterologous expression, purification and characterization of the influenza A virus M2e gene fused to Mycobacterium tuberculosis HSP70 (359-610) in prokaryotic system as a fusion protein[J]. Mol Biol Rep, 37, 2877-2883. doi: 10.1007/s11033-009-9846-2
-
Ebrahimi S M, Tebianian M, 2011: Influenza A viruses: why focusingon M2e-based universal vaccines[J]. Virus Genes, 42, 1-8. doi: 10.1007/s11262-010-0547-7
-
Ebrahimi S M, Dabaghian M, Tebianian M, Jazi M H, 2012: In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran[J]. Virology, 430, 63-72. doi: 10.1016/j.virol.2012.04.015
-
Ebrahimi S M, Tebianian M, Toghyani H, Memarnejadian A, Attaran H R, 2010: Cloning, expression and purification of the influenza A (H9N2) virus M2e antigen and truncated Mycobacterium tuberculosis HSP70 as a fusion protein in Pichia pastoris[J]. Protein Expr Purif, 70, 7-12. doi: 10.1016/j.pep.2009.11.001
-
Ernst W A, Kim H J, Tumpey T M, Jansen A D, Tai W, Cramer D V, Adler-Moore J P, Fujii G, 2006: Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines[J]. Vaccine, 24, 5158-5168. doi: 10.1016/j.vaccine.2006.04.008
-
Fan J, Liang X, Horton M S, Perry H C, Citron M P, Heidecker G J, Fu T M, Joyce J, Przysiecki C T, Keller P M, Garsky V M, Ionescu R, Rippeon Y, Shi L, Chastain M A, Condra J H, Davies M E, Liao J, Emini E A, Shiver J W, 2004: Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys[J]. Vaccine, 22, 2993-3003. doi: 10.1016/j.vaccine.2004.02.021
-
Fiers W, Neirynck S, Deroo T, Saelens X, Jou W M, 2001: Soluble recombinant influenza vaccines[J]. Philos Trans R Soc Lond B Biol Sci, 356, 1961-1963. doi: 10.1098/rstb.2001.0980
-
Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W, 2004: A "universal" human influenza A vaccine[J]. Virus Res, 103, 173-176. doi: 10.1016/j.virusres.2004.02.030
-
Frace A M, Klimov A I, Rowe T, Black R A, Katz J M, 1999: Modified M2 proteins produce heterotypic immunity against influenza A virus[J]. Vaccine, 17, 2237-2244. doi: 10.1016/S0264-410X(99)00005-5
-
Fu T M, Grimm K M, Citron M P, Freed D C, Fan J, Keller P M, Shiver J W, Liang X, Joyce J G, 2009: Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinantvirus like particle or conjugate vaccines in mice and monkeys[J]. Vaccine, 27, 1440-1447. doi: 10.1016/j.vaccine.2008.12.034
-
Grandea A G, 3rd, Olsen O A, Cox T C, Renshaw M, Hammond P W, Chan-Hui P Y, Mitcham J L, Cieplak W, Stewart S M, Grantham M L, Pekosz A, Kiso M, Shinya K, Hatta M, Kawaoka Y, Moyle M, 2010: Human antibodies reveal a protectiveepitope that is highly conserved among human and nonhuman influenza A viruses[J]. Proc Natl Acad Sci U S A, 107, 12658-12663. doi: 10.1073/pnas.0911806107
-
Haga T, Horimoto T. 2010. Animal Models to Study Influenza Virus Pathogenesis and Control The Open Antimicrobial Agents Journal, 2: 15-21.
-
Holsinger L J, Lamb R A, 1991: Influenza virus M2 integral membraneprotein is a homotetramer stabilized by formation of disulfide bonds[J]. Virology, 183, 32-43. doi: 10.1016/0042-6822(91)90115-R
-
Huleatt J W, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans R K, Umlauf S, Tussey L, Powell T J, 2008: Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin[J]. Vaccine, 26, 201-214. doi: 10.1016/j.vaccine.2007.10.062
-
Ionescu R M, Przysiecki C T, Liang X, Garsky V M, Fan J, Wang B, Troutman R, Rippeon Y, Flanagan E, Shiver J, Shi L, 2006: Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier[J]. J Pharm Sci, 95, 70-79. doi: 10.1002/jps.20493
-
Jazi M H, Dabaghian M, Tebianian M, Gharagozlou M J, Ebrahimi S M, 2012: In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine[J]. Virus Res, 167, 219-25. doi: 10.1016/j.virusres.2012.05.002
-
Kutzler M A, Weiner D B, 2008: DNA vaccines: ready for prime time?[J]. Nat Rev Genet, 9, 776-788. doi: 10.1038/nrg2432
-
Lamb R A, Zebedee S L, Richardson C D, 1985: Influenza virus M2 protein is an integral membrane protein expressed on theinfected-cell surface[J]. Cell, 40, 627-633. doi: 10.1016/0092-8674(85)90211-9
-
Lau L L, Cowling B J, Fang V J, Chan K H, Lau E H, Lipsitch M, Cheng C K, Houck P M, Uyeki T M, Peiris J S, Leung G M, 2010: Viral shedding and clinical illness in naturally acquired influenza virus infections[J]. J Infect Dis, 201, 1509-1516. doi: 10.1086/651176
-
Li X, Yang X, Li L, Liu H, Liu J, 2006: A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine[J]. Vaccine, 24, 3321-3331. doi: 10.1016/j.vaccine.2006.01.012
-
Liu W, Li H, Chen Y H, 2003: N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication[J]. FEMS Immunol Med Microbiol, 35, 141-146. doi: 10.1016/S0928-8244(03)00009-9
-
Liu W, Zou P, Ding J, Lu Y, Chen Y H, 2005: Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design[J]. Microbes Infect, 7, 171-177. doi: 10.1016/j.micinf.2004.10.006
-
Liu W, Peng Z, Liu Z, Lu Y, Ding J, Chen Y H, 2004: High epitope density in a single recombinant protein molecule of the extracellulardomain of influenza A virus M2 protein significantly enhances protective immunity[J]. Vaccine, 23, 366-371. doi: 10.1016/j.vaccine.2004.05.028
-
Lu X, Tumpey T M, Morken T, Zaki S R, Cox N J, Katz J M, 1999: A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans[J]. J Virol, 73, 5903-5911.
-
Macken C, Lu H, Goodman J, Boykin L, 2001: The value of a database in surveillance and vaccine selection[J]. International Congress Series, 1219, 103-106. doi: 10.1016/S0531-5131(01)00330-2
-
Mirzaei N, Mokhtari Azad T, Nategh R, Soleimanjahi H, Amirmozafari N, 2014: Construction of recombinant bacmid containing m2e-ctxb and producing the fusion protein in insect cell lines[J]. Iran Red Crescent Med J, 16, e13176-. doi: 10.5812/ircmj.13176.Epub2014Feb7
-
Mozdzanowska K, Furchner M, Zharikova D, Feng J, Gerhard W, 2005: Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies[J]. J Virol, 79, 5943-5951. doi: 10.1128/JVI.79.10.5943-5951.2005
-
Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L, Jr., Gerhard W, 2003: Induction of influenza type A virus-specificresistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2[J]. Vaccine, 21, 2616-2626. doi: 10.1016/S0264-410X(03)00040-9
-
Neirynck, Deroo, Saelens, Vanlandschoot, Jou, FiersW, 1999: A universal influenza A vaccine based on the extracellulardomain of the M2 protein[J]. Nat Med, 5, 1157-1163. doi: 10.1038/13484
-
Pinto L H, Holsinger L J, Lamb R A, 1992: Influenza virus M2 protein has ion channel activity[J]. Cell, 69, 517-528. doi: 10.1016/0092-8674(92)90452-I
-
Qazi K R, Wikman M, Vasconcelos N M, Berzins K, Stahl S, Fernandez C, 2005: Enhancement of DNA vaccine potency by linkage of Plasmodium falciparum malarial antigen gene fused with a fragment of HSP70 gene[J]. Vaccine, 23, 1114-1125. doi: 10.1016/j.vaccine.2004.08.033
-
Reed L J, Muench H A, 1983: Simple method for estimating fifty per cent endpoints[J]. Am. J. Epidemiol., 27, 493-497R.
-
Reid A H, Fanning T G, Janczewski T A, McCall S, Taubenberger J K, 2002: Characterization of the 1918 "Spanish" influenza virusmatrix gene segment[J]. J Virol, 76, 10717-10723.
-
Rimmelzwaan G F, Baars M, Claas E C, Osterhaus A D, 1998: Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methodsfor monitoring influenza virus replication in vitro[J]. J VirolMethods, 74, 57-66.
-
Sealy R, Surman S, Hurwitz J L, Coleclough C, 2003: Antibody response to influenza infection of mice: different patterns for glycoproteinand nucleocapsid antigens[J]. Immunology, 108, 431-439. doi: 10.1046/j.1365-2567.2003.01615.x
-
Segal B H, Wang X Y, Dennis C G, Youn R, Repasky E A, Manjili M H, Subjeck J R, 2006: Heat shock proteins as vaccine adjuvantsin infections and cancer[J]. Drug Discov Today, 11, 534-540. doi: 10.1016/j.drudis.2006.04.016
-
Seo S H, Hoffmann E, Webster R G, 2002: Lethal H5N1 influenza viruses escape host anti-viral cytokine responses[J]. Nat Med, 8, 950-954. doi: 10.1038/nm757
-
Swinkels W J, Hoeboer J, Sikkema R, Vervelde L, Koets A D, 2013: Vaccination induced antibodies to recombinant avian influenza A virus M2 protein or synthetic M2e peptide do not bind to the M2 protein on the virus or virus infected cells[J]. Virol J, 10, 206-. doi: 10.1186/1743-422X-10-206
-
Tompkins S M, Zhao Z S, Lo C Y, Misplon J A, Liu T, Ye Z, Hogan R J, Wu Z, Benton K A, Tumpey T M, Epstein S L, 2007: Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1[J]. Emerg Infect Dis, 13, 426-435. doi: 10.3201/eid1303.061125
-
Wang S, Zhang C, Zhang L, Li J, Huang Z, Lu S, 2008: The relative immunogenicity of DNA vaccines delivered by the intramuscularneedle injection, electroporation and gene gun methods[J]. Vaccine, 26, 2100-2110. doi: 10.1016/j.vaccine.2008.02.033
-
WHO , 2002: Draft WHO guidelines on the use of vaccines and antivirals during influenza pandemics[J]. Wkly Epidemiol Rec, 77, 394-404.
-
Zhao G, Lin Y, Du L, Guan J, Sun S, Sui H, Kou Z, Chan C C, Guo Y, Jiang S, Zheng B J, Zhou Y, 2010: An M2e-based multipleantigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses[J]. Virol J, 7, 9-. doi: 10.1186/1743-422X-7-9